SCHEMBL5542372

SCHEMBL5542372

O=[C]OC1CCN(c2ccc(C(F)(F)C(F)(F)F)cc2)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.39
CYP3A4 P08684 3/20 0.36
CA12 O43570 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
HRH4 Q9H3N8 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
DEGS1 O15121 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
AKR1C3 P42330 1/20 0.33
MLYCD O95822 2/20 0.33
ACACB O00763 2/20 0.33
GCK P35557 3/20 0.33
L3MBTL3 Q96JM7 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
LMNA P02545 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5535612 0.88 NOTUM (0.50) NOTUMCYP3A4CA12CA2CA9
SCHEMBL5541989 0.84 NOTUM (0.43) NOTUMHRH3ACACBL3MBTL1LMNA
SCHEMBL5542382 0.81 NOTUM (0.40) NOTUMCYP3A4CA12CA2CA9
SCHEMBL5540468 0.77 MAPT (0.47) GPR119AKR1C3L3MBTL3L3MBTL1LMNA
SCHEMBL5536217 0.77 MBTD1 (0.47) NOTUMCYP3A4GPR119ACACBL3MBTL3
SCHEMBL5542879 0.77 ADRB1 (0.49) NOTUMACACBPOLB
SCHEMBL5540469 0.75 TTR (0.36) NOTUMAKR1C3
SCHEMBL5539228 0.75 NOTUM (0.54) NOTUMHRH3ACACBL3MBTL1LMNA
SCHEMBL5538976 0.72 FFAR1 (0.38) HRH3ACACB
SCHEMBL5534353 0.71 FFAR4 (0.43) GPR119ACACBL3MBTL3L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOTUM 3827/4885CYP3A4 1683/4885CA12 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.